优化规则满足群众多元用药需求

Core Points - The eleventh batch of national drug centralized procurement has officially started, with new reporting rules that include an option for reporting by brand name to meet diverse medication needs [1][2] - Public medical institutions, including grassroots healthcare facilities, are required to participate in the reporting process from August 6 to August 25 [1] - The new reporting rules allow institutions to report either by drug name or by brand, providing flexibility in meeting clinical needs [1][2] Reporting Guidelines - If a reported brand is not selected, the corresponding volume will be managed by the province's main supply enterprise, and institutions must fulfill the agreement volume with that enterprise [2] - Institutions must ensure that total reported volumes are not less than 80% of the average procurement volume for 2023 and 2024 [2][3] - Institutions can adjust reported volumes based on actual needs, especially for drugs with fluctuating demand due to seasonal diseases or other factors [3] Clinical Needs and Procurement - The procurement policy encourages the use of selected drugs but allows for the purchase of non-selected drugs if clinical needs are not met [3] - Since 2018, a total of 435 drugs have been procured through 10 batches of centralized procurement, with ongoing adjustments to improve drug accessibility and quality for the public [3][4] - The procurement process aims to balance clinical stability, quality assurance, and fair competition among suppliers [4]